Effectiveness of epoprostenol in the management of pulmonary arterial hypertension - findings of an Australian retrospective chart review.
Pulmonary arterial hypertension (PAH) is a progressively fatal disease. Parenteral prostanoids, including IV epoprostenol, are the most effective therapies for PAH. As epoprostenol requires continuous infusion, therapy is challenging and use is managed by specialist units. To describe the clinical outcomes for the use of IV epoprostenol in an Australian pulmonary vascular disease unit and identify opportunities to improve its use. We conducted a retrospective chart review of all adult patients who received IV epoprostenol for PAH at Prince Charles Hospital. Data was collected at baseline, initiation of epoprostenol and quarterly to the end of the audit period or the discontinuation of epoprostenol. Descriptive statistics were performed and comparisons made to epoprostenol initiation. Kaplan-Meier curves were used to estimate survival outcomes. Thirty-nine patients received epoprostenol therapy. Most (87.2%) were female, had connective tissue disease (46.2%) or idiopathic PAH (35.9%) and had a WHO functional class of III or IV at initiation. The mean duration of epoprostenol therapy was 2.9 years. IV epoprostenol was associated with favourable outcomes; 1, 3 and 5-year survival rates since initiation of 90.0%, 75.8% and 68.2%; robust improvements in functional class; and improvements in 6-minute walking distance of 160.4 meters at 3 years. 94.9% patients experienced at least one drug-related adverse event and line complications were common. Epoprostenol therapy was associated with impressive survival rates and durable improvements in functional outcomes. Epoprostenol therapy is challenging, however it is manageable by the majority of patients with most experiencing positive, sustainable outcomes. This article is protected by copyright. All rights reserved.